Beth Psaila’s group apply state-of-the-art approaches to study normal and malignant megakaryocyte biology and bone marrow fibrosis, to identify new therapeutic targets for patients with myeloproliferative neoplasms. We are also interested in the role of platelets as biomarkers for early cancer detection.

Beth is an Associate Professor of Haematology and Group Leader at the MRC Weatherall Institute of Molecular Medicine. She is also a haematology consultant, specialising in the care of patients with myeloproliferative neoplasms, and a Senior Fellow in Medicine at New College Oxford. She split her training between the US and the UK, including at Clare College, Cambridge, Imperial College, Cornell, New York and the National Human Genome Research Institute, NIH.